Clarithromycin for Idiopathic Hypersomnia
Study Summary
This trial is evaluating whether the drug clarithromycin can help reduce sleepiness in people with narcolepsy or idiopathic hypersomnia.
- Narcolepsy
- Idiopathic Hypersomnia
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 1046 Patients • NCT04167670Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
What is the current capacity of participants in this clinical venture?
"Affirmative, clinicaltrials.gov indicates that this medical experiment is now enlisting participants. This study was initially broadcasted on September 4th 2019 and has since been revised on June 15th 2022. The team behind the trial currently needs 92 individuals across 1 site to complete the research project."
Are elderly individuals being admitted to this clinical trial?
"As per the trial's eligibility requirements, participants must fall between 18 and 60 years old to be included."
What risks do patients incur when taking Clarithromycin?
"While the efficacy of Clarithromycin is not yet confirmed, there are existing studies that support its safety. Thus, it received an approximate rating of 2 on our scale."
Are recruitment efforts underway for this trial?
"As indicated by the clinicaltrials.gov database, this venture is recruiting participants at present. This trial was initially posted on September 4th 2019 and has been modified as recently as June 15th 2022."
Who meets the prerequisites to join this investigation?
"This research is seeking 92 participants with idiopathic hypersomnia aged 18-60. In order to be considered, patients must have no wake-promoting medications in their system, narcolepsy type 2 or related diagnosis of the condition, not taken prebiotics/probiotics for 6 months prior to baseline measures and able to cease use of any current medication if applicable."
What results is the team hoping for from this experiment?
"The primary aim of this two week study is to measure any shifts in the gastrointestinal microbiome. Additionally, we are measuring changes in interleukin 1 alpha (IL-1α), interleukin 8 (IL-8), and interferon alpha (INF-α) levels which may correlate with a reduction in soporific cytokines leading to reduced daytime sleepiness."